Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2023-02-28

FDA Approved: KEVZARA — Supplemental Application (Sanofi-Aventis U.S. LLC)

View source ↗

Summary

FDA approved a supplemental application for KEVZARA (sarilumab), resulting in changes to the product label.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • KEVZARA (sarilumab)

Snippet

SUPPL AP for KEVZARA (SARILUMAB)